Degradation of Activated K-Ras Orthologue via K-Ras-specific Lysine Residues Is Required for Cytokinesis*

Received for publication, October 30, 2013, and in revised form, December 7, 2013. Published, JBC Papers in Press, December 13, 2013, DOI 10.1074/jbc.M113.531178

Kazutaka Sumita1,2, Hirofumi Yoshino3, Mika Sasaki4, Nazanin Majd4, Emily Rose Kahoud5, Hidenori Takahashi5, Koh Takeuchi6, Taruo Kuroda6, Susan Lee7, Pascale G. Charest7, Kosuke Takeda8,9, John M. Asara5, Richard A. Firtel10, Dimitrios Anastasiou11, and Atsuo T. Sasaki1

From the 1Division of Hematology Oncology, Department of Internal Medicine, University of Cincinnati Cancer Institute, Department of Neurosurgery, University of Cincinnati Neuroscience Institute, Brain Tumor Center University of Cincinnati, College of Medicine, Cincinnati, Ohio 45267, the 2Department of Medicine, Harvard Medical School, Division of Signal Transduction, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02115, the 3Biomedical Information Research Center, National Institute of Advanced Industrial Science and Technology, 2-3-26 Aomi, Koto, Tokyo 135-0064, Japan, the 4Department of Basic Medical Sciences, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie 514-8507, Japan, the 5Section of Cell and Developmental Biology, Division of Biological Sciences, University of California, San Diego, La Jolla, California 92093-0380, the 6Laboratory of Metabolic Medicine, Singapore Bioimaging Consortium, Agency for Science, Technology and Research, Singapore, 138667, Republic of Singapore, and the 7Division of Physiology and Metabolism, Medical Research Council National Institute for Medical Research, The Ridgeway, Mill Hill, London NW7 1AA, United Kingdom

**Background:** Targeting oncogenic K-Ras for cancer therapy has remained challenging.

**Results:** Ubiquitination specifically occurs on the activated K-Ras orthologue in *Dictyostelium* via evolutionary conserved K-Ras lysines, which promotes K-Ras protein degradation.

**Conclusion:** Our results indicate the existence of GTP-loaded K-Ras orthologue-specific degradation system in *Dictyostelium*.

**Significance:** This work reveals a novel negative feedback regulation for the K-Ras isoform, which is critical for cytokinesis in *Dictyostelium*.

Mammalian cells encode three closely related Ras proteins, H-Ras, N-Ras, and K-Ras. Oncogenic K-Ras mutations frequently occur in human cancers, which lead to dysregulated cell proliferation and genomic instability. However, mechanistic role of the Ras isoform regulation have remained largely unknown. Furthermore, the dynamics and function of negative regulation of GTP-loaded K-Ras have not been fully investigated. Here, we demonstrate RasG, the *Dictyostelium* orthologue of K-Ras, is targeted for degradation by polyubiquitination. Both ubiquitination and degradation of RasG were strictly associated with RasG activity. High resolution tandem mass spectrometry (LC-MS/MS) analysis indicated that RasG ubiquitination occurs at C-terminal lysines equivalent to lysines found in human K-Ras but not in H-Ras and N-Ras homologues. Substitution of these lysine residues with arginines (4KR-RasG) diminished RasG ubiquitination and increased RasG protein stability. Cells expressing 4KR-RasG failed to undergo proper cytokinesis and resulted in multinucleated cells. Ectopically expressed human K-Ras undergoes polyubiquitin-mediated degradation in *Dictyostelium*, whereas human H-Ras and a *Dictyostelium* H-Ras homologue (RasC) are refractory to ubiquitination. Our results indicate the existence of GTP-loaded K-Ras orthologue-specific degradation system in *Dictyostelium*, and further identification of the responsible E3-ligase may provide a novel therapeutic approach against K-Ras-mutated cancers.

Ras is a small GTPase that can cycle between a GTP-bound active state and a GDP-bound inactive state. GTP-loaded Ras elicits an array of downstream signaling such as Raf/MEK/ERK and PI3K/AKT pathways to promote cell survival and proliferation (1–5).

Mammalian cells encode four closely related Ras proteins, H-Ras, N-Ras, K-Ras 4A, and K-Ras 4B that are highly homologous in the first 85% of the protein and share a C-terminal CAAX box that targets them for farnesylation. The C-terminal hypervariable region (HVR)4 renders distinctive roles of Ras isoforms. The HVR of K-Ras 4B (hereafter called K-Ras), a dominant K-Ras isoform, contains a poly-basic, lysine-rich, cluster that is required for K-Ras plasma membrane localization. The HVRs of the other Ras isoforms, including K-Ras 4A, another minor K-Ras isoform, provide palmitoylation site(s) for targeting to the plasma membrane (6–10). Extensive research within the past two decades has shown that Ras isoforms differ in their ability to activate downstream effectors and promote transformation (11–13). In mouse tumor models, only the constitutively active K-Ras mutant, but not H-Ras or N-Ras mutants, promotes colorectal carcinogenesis and hyperprolif-

---

* This work was supported in part by National Institutes of Health Grants 2P01CA120964 (to J. M. A.) and 5P30CA066516 (to J. M. A.) and the University of Cincinnati (to A. T. S.).

1 These authors contributed equally to this work.

2 Supported in part by the American Association of Neurological Surgeons.

3 To whom correspondence should be addressed: UC Cancer Inst., Dept. of Internal Medicine, Div. of Hematology Oncology, UC Neuroscience Institute, Dept. of Neurosurgery, Brain Tumor Center, University of Cincinnati, College of Medicine, Cincinnati, OH 45267. Tel.: 513-558-2160; Fax: 513-558-6703; E-mail: atsuos.sasaki@uc.edu.

4 The abbreviations used are: HVR, hypervariable region; CHX, cycloheximide; 7KR-RasG, seven lysine residues in the membrane-targeting region substituted for arginine residues; 4KR-RasG, four lysines found to be ubiquitinated are substituted with arginines.
eration of endoderm progenitor cells (1, 3, 14, 15). In human cancers, K-Ras is the most frequently mutated Ras isoform. Furthermore, K-Ras mutations are associated with poor clinical prognosis and resistance to chemotherapy (6, 8, 16–18). Despite numerous attempts, a small molecule inhibitor for K-Ras is yet to be developed for clinical use. Identification of KRas-specific regulatory mechanisms is likely to provide important insights into the development of novel therapeutic applications for K-Ras-mutated tumors.

To date, many of the physiological roles of Ras have been identified through studies using model organisms. However, not all model organisms have both H-Ras and K-Ras isoforms. *Saccharomyces cerevisiae*, a unicellular organism, has H-Ras homologue genes Ras1 and Ras2, but it does not encode for a K-Ras orthologue. *Caenorhabditis elegans* and *Drosophila melanogaster* have a single K-Ras orthologous gene but not an H-Ras orthologue. *Dictyostelium discoideum*, a social amoeba that has the ability to alternate between a unicellular and a multicellular form, has both K-Ras and H-Ras orthologues. Therefore, to investigate whether ubiquitination comprises an evolutionarily conserved mechanism for Ras regulation, we utilized the *Dictyostelium* system.

**EXPERIMENTAL PROCEDURES**

**Materials**—Anti-FLAG (M2) antibody and 3× FLAG peptide were from Sigma Aldrich; anti-Ras (Ab-3) antibody was from EMD Millipore; and anti-ubiquitin antibody (P4D1) was from Santa Cruz Biotechnology. FLAG-tagged Ras mutants were generated by the standard PCR method and subcloned into pEXP4(H9262). All constructs were sequenced. We produced GST-RBD in BL21 bacteria (Stratagene) and purified it on glutathione-Sepharose (Amersham Biosciences) per the manufacturer’s instructions.

**Cell Culture**—All cell lines were cultured axenically in HL5 medium at 22 °C. Transformants were maintained in 40 μg/ml G418.

**Tandem Mass Spectrometry Analysis**—FLAG-RasG expressing RasG-null cells were grown exponentially in HL5 medium. The a billion of FLAG-RasG/RasG cells were then collected and treated with cycloheximide. Consistent with this hypothesis, the slow-migrating ladder bands was detected with anti-Ras antibody, indicating that ladder bands were modified forms of RasG protein. The increment of RasG expression after 30 min (Fig. 1B). The half-life of the RasG protein was further shortened by chemoattractant (cAMP) stimulation. These results suggest that RasG protein stability can be dynamically decreased by extracellular stimuli.

To investigate whether ubiquitin-mediated degradation system could account for RasG destabilization, RasG was immunoprecipitated with anti-FLAG resin from WT-RasG∆RasG cells. Immunoprecipitated RasG was detected with anti-FLAG antibody as an expected band (∼25 kDa). The anti-FLAG antibody also detected slower migrating bands above the 30-kDa molecular mass marker, which were not detected in the control wild-type cells (Ax3). A similar band ladder pattern was also detected with anti-Ras antibody, indicating that ladder bands were modified forms of RasG protein. The increment of RasG ladder bands was ∼9 kDa, which is equivalent to the size of ubiquitin. Consistent with this hypothesis, the slow-migrating RasG bands were recognized with anti-ubiquitin antibody (Fig. 1C). These results indicated that RasG has a ubiquitinated form and that an evolutionarily conserved mechanism of K-Ras regulation by ubiquitination may exist in *Dictyostelium*.

**RasG Undergoes Activation-dependent Ubiquitination**—Next, we investigated whether RasG protein stability might be modulated by RasG activation and/or its downstream signaling. We introduced a point mutation (Thr-35 to Ala) in RasG that interferes with the GTP-mediated switch transition and therefore abrogates effector binding of Ras (14, 15, 20, 21). To study the mutant RasG stability, we used vegetative *Dictyostelium* cells rather than developmentally competent cells because mutation of RasG can affect *Dictyostelium* development (16−18, 22, 23). The WT-RasG∆RasG cells or T35A-RasG∆RasG cells were grown to exponential phase and then treated with cycloheximide. Consis-
tent with the result seen in developed cells, CHX treatment led to a 50% decrease in wild-type RasG protein levels within 30 min (Fig. 2A) in the vegetative growth condition. In contrast, the half-life of T35A-RasG protein was significantly extended.

To investigate whether RasG ubiquitination is triggered by the downstream effector pathway of RasG, ubiquitination levels of wild-type RasG and T35A-RasG were assessed. Non-ubiquitinated T35A-RasG expression levels were 2 times more than WT-RasG. However, the ubiquitination level of T35A-RasG was 3 times less than that of WT-RasG. Taking into consideration the increased protein stability of T35A-RasG, these results suggest that RasG induces its own ubiquitination via downstream effector pathway for its degradation. Notably, mono-ubiquitinated T35A-RasG was still detectable, albeit at lower levels compared with wild-type RasG. This suggests the existence of yet another RasG ubiquitination pathway that is independent of RasG activity. However, such a pathway may not be relevant for RasG degradation, as T35A-RasG is more stable compared with wild-type RasG (Fig. 2B).

**Ubiquitination Sites of RasG Are Located in the Guanine Nucleotide-binding Domain and C-terminal Hypervariable Region**

To gain further insight into the role of RasG ubiquitination, we determined ubiquitination sites in RasG. FLAG-RasG protein and its ubiquitinated forms were purified with

---

**FIGURE 1. RasG, Dictyostelium K-Ras homologue, undergoes polyubiquitination.** A, schematic diagram of G-domain of Ras (upper panel). The C-terminal HVRs of RasG and human Ras isoforms are aligned (lower panel). B, the FLAG-tagged WT-RasG/ΔRasG cells were treated with 100 μg/ml CHX for indicated times, in the presence (+) or absence (−) of 10 μM of cAMP, and cell extracts were analyzed with anti-FLAG antibody. Relative protein levels of RasG were quantified and are shown on the right. These blots are representative of two separate experiments. C, RasG undergoes polyubiquitination (Poly-Ub.RasG). FLAG-tagged RasG was immunoprecipitated (IP) from total cell lysate (TCL) of FLAG-tagged RasG stably expressing RasG knock-out cells (FLAG-RasG/ΔRasG), and immunoblotted with the indicated antibodies. Wild-type cells, Ax3 cell line, were used as control. Ubiquitinated Ras is indicated with arrowheads. These blots are representative of three separate experiments.
Negative Feedback Regulation of K-Ras by Ubiquitination

Polyubiquitination and degradation of RasG requires RasG activation and its downstream effector. A, T35A-RasG mutant increased protein stability. The WT- and T35A-RasG stably expressing cells were treated with 100 μg/ml CHX for indicated times, and cell extracts were analyzed with anti-FLAG antibody. Relative protein levels of RasG were quantified by ImageJ software and shown in the bottom panel. These blots are representative of two separate experiments. B, T35A-RasG mutant decreased ubiquitination level. FLAG-tagged WT- and T35A-RasG were immunoprecipitated (IP) from total cell lysate (TCL) of FLAG-tagged RasG stably expressing RasG knock-out cells (FLAG-RasG/ΔRasG) and immunoblotted (IB) with the indicated antibodies. Wild-type cells, Ax3 cell line, were used as control. Ubiquitinated Ras is indicated with arrowheads. short expos., short exposure; Poly-Ub., polyubiquitination.

To further verify the result, we immunoprecipitated RasG for Western blot analysis and then blotted the membrane with linkage specific ubiquitin antibodies. We observed a strong signal by Lys-48-linkage-specific ubiquitin antibody. Next we tested whether polyubiquitinated form of RasG contain Lys-63-linked ubiquitin. The anti-Lys-63-linked ubiquitin antibody displayed robust signal in the total cell lysate fraction, which are distinctive pattern compared with the anti-Lys-48-linked ubiquitin antibody, consistent with previous reports (26–28). However, we could not detect Lys-63-linked ubiquitin signal in the RasG-immunoprecipitated sample (Fig. 4A). These data are consistent with the LC-MS/MS result (Fig. 3D).

To further verify the finding, we examined the effect of proteasome inhibitors on ubiquitination of RasG. We tested four proteasome inhibitors, which have been widely used, and increased concentration to 5~10 fold the commonly used dose. Unfortunately, lactacystin, epoxomicin, and ALLN did not induce any detectable changes of ubiquitination signal of cellular proteins. This is in agreement with the previous studies that Dictyostelium cellular proteins were refractory to MG132, MG262, and lactacystin, presumably due to the restricted permeability to and high rate of drug exclusion from the Dictyostelium or both (29, 30). At 100 μM concentration, the treatment of MG132 slightly induced accumulation of the polyubiquitinated cellular proteins (Fig. 4A). Under this condition, there was further accumulation of the Lys-48-ubiquitinated RasG. This suggests that Lys-48-linked ubiquitination of RasG is degraded, if not all, via the ubiquitin-proteasome system.

C-terminal Lysine Cluster Ubiquitination Leads to RasG Destabilization—To further investigate the function of ubiquitination in the HVR of RasG, we made a RasG mutant where all four lysines found to be ubiquitinated are substituted with arginines (4KR-RasG). We also made a mutant that has the seven lysine residues in the membrane-targeting region substituted for arginine residues (7KR-RasG) (Fig. 4, A and B). FLAG-tagged 4KR-RasG and 7KR-RasG mutants were stably expressed in RasG knock-out cells (FLAG-RasG/ΔRasG) and immunoblotted (IB) with the indicated antibodies. Wild-type cells, Ax3 cell line, were used as control. Ubiquitinated Ras is indicated with arrowheads. short expos., short exposure; Poly-Ub., polyubiquitination.

FIGURE 2. Polyubiquitination and degradation of RasG requires RasG activation and its downstream effector. A, T35A-RasG mutant increased protein stability. The WT- and T35A-RasG stably expressing cells were treated with 100 μg/ml CHX for indicated times, and cell extracts were analyzed with anti-FLAG antibody. Relative protein levels of RasG were quantified by ImageJ software and shown in the bottom panel. These blots are representative of two separate experiments. B, T35A-RasG mutant decreased ubiquitination level. FLAG-tagged WT- and T35A-RasG were immunoprecipitated (IP) from total cell lysate (TCL) of FLAG-tagged RasG stably expressing RasG knock-out cells (FLAG-RasG/ΔRasG) and immunoblotted (IB) with the indicated antibodies. Wild-type cells, Ax3 cell line, were used as control. Ubiquitinated Ras is indicated with arrowheads. short expos., short exposure; Poly-Ub., polyubiquitination.

anti-FLAG resin followed by FLAG peptide elution. The bands migrating at the positions for mono- and diubiquitinated form of RasG were digested by trypsin and subjected to LC-MS/MS analysis. Major ubiquitination sites were found at Lys residues 169, 173, 176, and Lys-178, and a minor fraction of Lys-117 ubiquitination was found (Fig. 3 A–C). The four major ubiquitination sites are located in the C-terminal HVR. HVR can be subdivided into two regions, the linker region and membrane-targeting region (19, 20, 24, 25). Interestingly, all four ubiquitinated lysine residues are evolutionarily conserved from Dictyostelium RasG to human K-Ras4A and K-Ras4B and are all located in the linker region (Fig. 3A).

RasG Receives Lys-48-linked Polyubiquitination—Linkage-specific ubiquitination often determine the fate of the ubiquitinated proteins. Potentially seven different types of ubiquitin linkages can be formed, depending on whether the ubiquitins are attached to Lys-6, Lys-11, Lys-27, Lys-29, Lys-33, Lys-48, or Lys-63 on the ubiquitin (26–28). To determine the ubiquitin linkage, we undertook the LC-MS/MS analysis. LC-MS/MS detected 90% of entire ubiquitin protein from the diubiquitinated RasG. Strikingly, we found that diubiquitinated RasG contained Lys-48-linked ubiquitination in the diubiquitinated form of RasG (Fig. 3D), whereas there was no ubiquitinated fragment of other regions detected, including Lys-63.

To further verify the result, we immunoprecipitated RasG for Western blot analysis and then blotted the membrane with linkage specific ubiquitin antibodies. We observed a strong signal by Lys-48-linkage-specific ubiquitin antibody. Next we tested whether polyubiquitinated form of RasG contain Lys-63-linked ubiquitin. The anti-Lys-63-linked ubiquitin antibody displayed robust signal in the total cell lysate fraction, which are distinctive pattern compared with the anti-Lys-48-linked ubiquitin antibody, consistent with previous reports (26–28). However, we could not detect Lys-63-linked ubiquitin signal in the RasG-immunoprecipitated sample (Fig. 4A). These data are consistent with the LC-MS/MS result (Fig. 3D).

Unfortunately, lactacystin, epoxomicin, and ALLN did not induce any detectable changes of ubiquitination signal of cellular proteins. This is in agreement with the previous studies that Dictyostelium cellular proteins were refractory to MG132, MG262, and lactacystin, presumably due to the restricted permeability to and high rate of drug exclusion from the Dictyostelium or both (29, 30). At 100 μM concentration, the treatment of MG132 slightly induced accumulation of the polyubiquitinated cellular proteins (Fig. 4A). Under this condition, there was further accumulation of the Lys-48-ubiquitinated RasG. This suggests that Lys-48-linked ubiquitination of RasG is degraded, if not all, via the ubiquitin-proteasome system.

C-terminal Lysine Cluster Ubiquitination Leads to RasG Destabilization—To further investigate the function of ubiquitination in the HVR of RasG, we made a RasG mutant where all four lysines found to be ubiquitinated are substituted with arginines (4KR-RasG). We also made a mutant that has the seven lysine residues in the membrane-targeting region substituted for arginine residues (7KR-RasG) (Fig. 4, A and B). FLAG-tagged 4KR-RasG and 7KR-RasG mutants were stably expressed in RasG knock-out cells (FLAG-RasG/ΔRasG) and immunoblotted (IB) with the indicated antibodies. Wild-type cells, Ax3 cell line, were used as control. Ubiquitinated Ras is indicated with arrowheads. short expos., short exposure; Poly-Ub., polyubiquitination.

J. M. Asara, unpublished observations.
**A** **Major ubiquitination sites of RasG**

![Diagram showing ubiquitination sites of RasG](image)

**B** **Ubiquitination sites of mono-Ub.-RasG**

![Diagram showing ubiquitination sites of mono-Ub.-RasG](image)

**C** **Ubiquitination sites of di-Ub.-RasG**

![Diagram showing ubiquitination sites of di-Ub.-RasG](image)

**D** **Ubiquitination sites of ubibuiqin from di-Ub.RasG**

![Diagram showing ubiquitination sites of ubibuiqin from di-Ub.RasG](image)
Negative Feedback Regulation of K-Ras by Ubiquitination

FIGURE 4. Lys-48-linked ubiquitination of RasG regulates RasG stability and cytokinesis. A, WT-RasG receives Lys-48-linked polyubiquitination. FLAG-tagged WT- and 7KR-RasG mutants cells were treated with the indicated proteasome inhibitors for 40 min. WT- and 7KR-RasG were immunoprecipitated (IP) from total cell lysate (TCL) and immunoblotted (IB) with the indicated antibodies. Only MG132 displayed inhibition of proteasome inhibition, leading accumulation of polyubiquitinated proteins. B, 4KR- and 7KR-RasG mutants decreased ubiquitination level. Ubiquitination level of the indicated RasG mutants was assessed as in Fig. 1A. These blots are representative of two separate experiments. Relative polyubiquitinated RasG levels were assessed by quantification of poly- and non ubiquitinated (Ub) RasG signal intensity by ImageJ software. Polyubiquitination signal was divided by non-ubiquitinated RasG signal to estimate poly-ubiquitinated RasG level.

FIGURE 3. Ubiquitination of RasG occurred on K-Ras specific lysine residues. A, ubiquitination (Ub) sites in RasG was identified by tandem mass spectrometry and shown in the red boxed lysine residues. The sequence of the RasG ubiquitination sites and corresponding region of human Ras isoforms are aligned (lower panel). The identified ubiquitination sites were mutared to arginine residues in 4KR and 7KR RasG mutants as shown in the lower panel. B–D, diagram of LC/MS/MS identified in vivo ubiquitination sites in RasG and ubiquitin. FLAG-tagged RasG was stable expressed and immunoprecipitated with anti-FLAG antibody. The IP was run out on SDS-PAGE, stained with Coomassie, and the band corresponding to monoubiquitinated RasG (Ub) and diubiquitinated (d Ub) RasG (C and D) was cut out, and isolated and subjected to tryptic digest and LC/MS/MS analysis. Amino acid coverage map showing the tryptic peptides sequenced by LC-MS/MS are in dark green and the detected ubiquitination sites are highlighted in magenta. Light green and blue highlight oxidations of Asn/Gln and Met, which are most likely an in vitro processing artifact.

expressed into RasG-null cells, and their ubiquitination levels were assessed. Fig. 4B shows that the ubiquitination level of 7KR-RasG was 9 times lower than that of wild-type RasG. The results of Figs. 1B and 2A suggest that activated RasG receives polyubiquitination. Importantly, we found that polyubiquitination levels were increased ~2 times in G12V-RasG and Q61L-RasG constitutively active mutants, which are locked in GTP-bound state, compared with that of wild-type RasG. Consistent
with the results of Figs. 1 and 2, this suggests the activated form of RasG receives polyubiquitination. To further verify this, we introduce mutation of 4KR into Q61L-RasG rather than WT-RasG because 4KR mutation may reduce RasG activation by non-ubiquitin-related pathway. Strikingly, 4KR-Q61L-RasG reduced ubiquitination level, 17 times less than Q61L-RasG (Fig. 4B). The results indicated that these four lysine residues found by mass spectrometry analysis were bona fide ubiquitination sites. However, both 7KR- and 4KR-Q61L mutants still receive a small fraction of polyubiquitination, suggesting that there is another site(s) for polyubiquitination. It is also possible that the mutation of the C-terminal lysine may lead to ubiquitination of another site(s), which is otherwise not ubiquitinated.

We have further investigated the role of the HVR ubiquitination on RasG protein stability. As shown in Fig. 4C, wild-type RasG protein level was quickly decreased after CHX treatment, while 4KR- and 7KR-RasG mutants significantly increased protein stability. Consistent with the elevated Lys-48-linked polyubiquitination level (Fig. 4, A and B), the degradation of G12V- and Q61L-RasG was faster than that of wild-type RasG. Importantly, Q61L-RasG destabilization was completely reversed by the four-lysine residue mutation. These results indicate that ubiquitination of HVR in RasG regulates RasG protein stability.

RasG Ubiquitination Pathway Is Critical for Cytokinesis—RasG is critical for cytokinesis (20, 21, 31). Recently, it has been shown that Cdc42, a Rho family GTPase essential for cytokinesis, is down-regulated during mitotic exit, which is required for proper cytokinesis (22, 23, 32). To assess the functional significance of RasG ubiquitination, we assessed cytokinesis of wild-type- and 4KR-RasG-expressing RasG-null cells using suspension culture where cytokinesis-deficient mutants become multinucleated (20, 24, 25, 33, 34). Consistent with previous reports, RasG-null cells became multinucleated after 3 days of shaking culture in suspension. The expression of wild-type RasG prevented the emergence of multinucleated cells (Fig. 4D). However, the expression of 4KR-RasG mutant failed to reverse the cytokinesis defect of RasG-null cells.

Next, to test whether KR-mutant retains activity, we first performed a biochemical assay. The GST-Ras-binding domain pulldown assay reveals that 7KR mutant has high basal activity, which is more than Q61L mutant. Thus, the 7KR mutant undergoes GTP loading and binds to its effector molecules (Fig. 5A). However, the 7KR mutant may no longer be the same as WT-RasG because the mutant protein level is higher than the WT, similar to its basal activation levels.

FIGURE 5. Effect of ubiquitination on the basal RasG activity and developmental activity. A, 7KR-RasG increases basal activity. RasG wild-type (WT) or mutants were stably expressed in ΔRasG cells, and their activation level was analyzed by a GST-RBD pulldown assay of Ras as described in Ref. 51. Q61L-RasG has much higher basal activity than WT-RasG. 7KR mutant increases basal activity, presumably because the 7KR-RasG could evade from the activation-dependent RasG degradation. B, 7KR-RasG cells retain developmental activity, similar to WT-RasG cells. RasG wild-type (WT) or 7KR mutant were stably expressed in ΔRasG cells and plated on non-nutrient agar to induce the developmental process as described previously (52, 53). Although the impeding mutation of GTPase activity of RasG has shown to attenuate the developmental process (35), the 7KR-RasG cells displayed highly comparable developmental progression to WT-RasG cells.

IB, immunoblot.
Therefore, we next examined whether 7KR-RasG has a role in developmental process of Dictyostelium, which requires proper regulation of chemotaxis and gene expression. The cells were seeded on the development plate at various cell densities, and their developmental processes were monitored for the developmental process for 48 h. Interestingly, although constitutive RasG activation has been shown to lead to developmental defects in Dictyostelium (35), the 7KR-RasG mutant cells have normal developmental functioning, indistinguishable to that of WT-RasG cells (Fig. 5B). The biochemical and developmental analyses suggest that ubiquitin-mediated regulation of RasG is not involved in the normal developmental process even though the 7KR-mutant has higher basal Ras activity. It should be noted that cells under the developmental assay condition, which does not have nutrients, do not proliferate. Furthermore, cytokinesis defect of RasG cells are only prominent when they are cultured in suspension (20, 24, 25). Thus, the cytokinesis defect of RasG mutant cells was suppressed in the development plate condition, whereas human H-Ras is refractory to ubiquitination in Dictyostelium. A schematic diagram of K-Ras and H-Ras chimeric mutants (left). Human K-Ras, H-Ras, and chimeric mutants were stably expressed in ΔHras cells, and their protein stability was assessed as in Fig. 2. These blots are representative of two separate experiments. IB, immunoblot.

H-Ras Homologue, RasC, Does Not Undergo Ubiquitination—Next, we investigated whether other Ras isoforms in Dictyostelium are ubiquitinated similarly to RasG. To test this possibility, we focused on Dictyostelium RasC, a functional orthologue of human H-Ras, which is a critical mediator of chemotactant-induced PI3K and AKT activation (36, 38). RasC does not have lysine residues in its linker region, and RasC shares several residues in the linker region with mammalian H-Ras (Fig. 6A). FLAG-tagged wild-type RasC was stably expressed into RasC-null mutant cells (WT-RasC/ΔRasC). The expression of RasC complemented the developmental defect of RasC-null cells indicating that the exogenously expressed RasC protein was functional. Unlike RasG, we did not detect ubiquitination of RasC (Fig. 6B). We also expressed G12V-RasC, a mutant that is constitutively bound to GTP and found that G12V-RasC did not undergo ubiquitination either. Consistent with this finding, both wild-type and G12V-RasC proteins are very stable (Fig. 6C). These results reveal that RasC is refractory to ubiquitination-mediated degradation.

Ubiquitination Specifically Occurs on K-Ras Orthologue, but Not on H-Ras Orthologue, in Dictyostelium—Sequence alignment revealed that the identified ubiquitination sites of RasG were conserved in mammalian K-Ras 4A and 4B, but not in H-Ras (Figs. 1A and 6A). Therefore, we next examined whether human K-Ras protein could be recognized for ubiquitination in Dictyostelium cells. Human G12V-K-Ras4B was stably expressed into RasG-null cells and immunoprecipitated with anti-FLAG agarose. Western blotting with anti-ubiquitin antibody revealed that G12V-K-Ras was highly ubiquitinated in Dictyostelium at levels similar to RasG ubiquitination (Fig. 6D).
To further examine whether human Ras proteins undergo ubiquitination in Dictyostelium in an isoform-specific manner, human wild-type and G12V-H-Ras were stably expressed in Dictyostelium. Fig. 6D, right panel, shows that in Dictyostelium, ubiquitination of wild-type H-Ras and G12V-H-Ras was not observed in contrast to the ubiquitination of K-Ras. The most significant difference of K-Ras and H-Ras is their C-terminal HVR region. To further examine the importance of K-Ras HVR for ubiquitination, we have generated a chimeric H-Ras protein that harbors the HVR of K-Ras (H-Ras/K) and a chimeric K-Ras that harbors the HVR of H-Ras (K-Ras/H). Fig. 6E shows that a half-life of K-Ras/H protein prolonged about six times more than that of wild-type K-Ras, a half-life of H-Ras/K mutant was about three times less than wild-type H-Ras.

Using biochemical and genetic approaches, we have found that RasG, a Dictyostelium K-Ras orthologue, undergoes ubiquitination and that the extent of ubiquitination is dependent on downstream effector signaling. Ubiquitination specifically occurred on lysine residues that are conserved in K-Ras HVR linker domain. RasG ubiquitination regulates RasG protein levels and is required for proper cytokinesis. Ectopically expressed human K-Ras can be polyubiquitinated in Dictyostelium. However, human H-Ras and Dictyostelium RasC, a H-Ras orthologue, are refractory to ubiquitination. Thus, Dictyostelium has a ubiquitination system that is specific for activated RasG that can also target human K-Ras.

Recently, three types of ubiquitin-mediated Ras regulatory pathways have been discovered: 1) ubiquitination of Ras isoforms at Lys-117 or Lys-147 leads to RasGEF-independent Ras activation (14, 39, 40, 45); 2) ubiquitination of H-Ras by the E3-ubiquitin ligase RabEX5 results in H-Ras endomembrane activation (14, 39, 40, 45); 2) ubiquitination of H-Ras by the E3 ubiqutination system that is specific for activated RasG that, a ubiquitination at the K-Ras-specific lysines may alternate subunits, we assume that the activated RasG/K-Ras-specific E3 ligase may form a protein complex that contains subunit binding domain. Because E3 ligase often consists of several subunits, we assume that the activated RasG/K-Ras-specific E3 ligase may form a protein complex that contains subunit binding domain. We also speculate that RasG/K-Ras E3 ligase may recognize GTP-RasG/KRas, which is in the binding status with its effector, to specifically regulate effector pathway. This could be analogous mechanism to the ubiquitin-activate RasGEF-dependent effector selection of Ras, which we have reported recently (14, 39, 45). We expect that active RasG-specific E3 ligase has a role in cytokinesis, based on our observation. Thus, Dictyostelium RasC mutants that have a cytokinesis defect may contain the RasG E3 ligase. Future biochemical purification and/or genetic analysis should reveal the responsible machinery for RasG ubiquitination.

Currently, it is unclear whether mammalian cells have a similar mechanism of K-Ras regulation. Several studies in human cancers revealed that increased Ras protein levels in tumors can be attributed to suppressing microRNAs against Ras and/or genomic amplification of the Ras locus. It is possible that a K-Ras-specific degradation system may act as tumor suppressor and thus suppressed in cancers. Consistent with this notion, it has been shown that expression of proapoptotic Ras effectors such as Nore1 and RASSFs (Ras association domain family) are frequently down-regulated by promoter methylation or chromosomal rearrangement in various cancers (46–50). These observations support the possibility that K-Ras degradation pathway might be conserved from Dictyostelium to human, which could be down-regulated in cancer cells. Future studies to identify an E3 ligase specific to RasG and K-Ras are required and may provide a novel approach to target K-Ras-mutated cancers.

Acknowledgments—We gratefully acknowledge the members of the University of Cincinnati Cancer Institute, the UC Brain Tumor Center and the Izayoi Meeting for stimulating discussions and helpful suggestions. Dr. Melanie Cushion, Dr. Antonis Koromilas, Mary Kemper, Dillon Chen, and Janice Connolly for help in critical reading and preparing this manuscript. We sincerely thank Dr. Lewis Cantley for the critical comments, support, and encouragement. We also thank Drs. Ronald Warrick, Sarah Kozma, Carol Mercer, and George Thomas for generous support and feedback. We thank Xuemei Yang and Min Yuan for help with mass spectrometry experiments.

REFERENCES

1. Quinlan, M. P., Quatela, S. E., Philips, M. R., and Settleman, J. (2008) Activated Kras, but not Hras or Nras, may initiate tumors of endodermal origin via stem cell expansion. Mol. Cell Biol. 28, 2659–2674
2. Karnoub, A. E., and Weinberg, R. A. (2008) Ras oncogenes: split personalities. Nat. Rev. Mol. Cell Biol. 9, 517–531
3. Haigis, K. M., Kendall, K. R., Wang, Y., Cheung, A., Haigis, M. C., Glickman, J. N., Niwa-Kawakita, M., Sweet-Cordero, A., Sebrell-Leopold, J., Shannon, K. M., Settleman, J., Giovannini, M., and Jacks, T. (2008) Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat. Genet. 40, 600–608
4. Wennerberg, K., Rossman, K. L., and Der, C. J. (2005) The Ras superfamily at a glance. J. Cell. Sci. 118, 843–846
5. Vetter, I. R., and Wittinghofer, A. (2001) The guanine nucleotide-binding switch in three dimensions. Science 294, 1299–1304
6. Downward, J. (2003) Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer 3, 11–22
7. Hancock, J. F. (2003) Ras proteins: different signals from different locations. Nat. Rev. Mol. Cell Biol. 4, 373–384
8. Malumbres, M., and Barbacid, M. (2003) RAS oncogenes: the first 30 years. Nat. Rev. Cancer 3, 459–465
9. Prior, I. A., and Hancock, J. F. (2012) Ras trafficking, localization and compartmentalized signalling. Semin. Cell Dev. Biol. 23, 145–153
10. Mor, A., and Phillips, M. R. (2006) Compartmentalized ras/mek signaling. Annu. Rev. Immunol. 24, 771–800
11. Sasaki, A. T., Chun, C., Takeda, K., and Firtel, R. A. (2004) Localized Ras signaling at the leading edge regulates PI3K, cell polarity, and directional cell movement. J. Biol. Chem. 167, 505–518
12. Keller, J. W., Haigis, K. M., Franklin, J. L., Whitehead, R. H., Jacks, T., and Coffey, R. J. (2007) Oncogenic K-Ras subverts the antiapoptotic role of N-Ras and alters modulation of the N-RAS: gelsolin complex. Oncogene 26, 3051–3059
13. Voice, J. K., Klemke, R. L., Le, A., and Jackson, J. H. (1999) Four human ras homologs differ in their abilities to activate Raf-1, induce transformation, and stimulate cell motility. J. Biol. Chem. 274, 17164–17170
14. Sasaki, A. T., Carracedo, A., Locasale, J. W., Anastasiou, D., Takeuchi, K.,
Negative Feedback Regulation of K-Ras by Ubiquitination

Kahoud, E. R., Haviv, S., Asara, J. M., Pandolfi, P. P., and Cantley, L. C. (2011) Ubiquitination of K-Ras enhances activation and facilitates binding to select downstream effectors. Sci. Signal. 4, ra13

15. Spoermer, M., Herrmann, C., Vetter, I. R., Kalbitzer, H. R., and Wittinghofer, A. (2001) Dynamic properties of the Ras switch Iregion and its importance for binding to effectors. Proc. Natl. Acad. Sci. U.S.A. 98, 4944–4949

16. Khosla, M., Spiegelman, G. B., and Weeks, G. (1996) Overexpression of an activated rasG gene during growth blocks the initiation of Dictyostelium development. Mol. Cell. Biol. 16, 4156–4162

17. Thiery, R., Robbins, S., Khosla, M., Spiegelman, G. B., and Weeks, G. (1992) The effects of expression of an activated rasG mutation on the differentiation of Dictyostelium. Biochem. Cell Biol. 70, 1193–1199

18. Jaffer, Z. M., Khosla, M., Spiegelman, G. B., and Weeks, G. (2001) Expression of activated Ras during Dictyostelium development alters cell localization and changes cell fate. Development 128, 907–916

19. Gorfe, A. A., Hanzl-Bayer, M., Abankwa, D., Hancock, J. F., and McCammon, J. A. (2007) Structure and dynamics of the full-length lipid-modified H-Ras protein in a 1,2-dimyristoylphosphoglycerol-3-phosphocholine bilayer. J. Med. Chem. 50, 674–684

20. Tuxworth, R. I., Cheetham, J. L., Machesky, L. M., Spiegelman, G. B., Weeks, G., and Insall, R. H. (1997) Dictyostelium RasG is required for normal motility and cytokinesis, but not growth. J. Cell Biol. 138, 605–614

21. Bolourani, P., Spiegelman, G. B., and Weeks, G. (2010) Ras proteins have multiple functions in vegetative cells of Dictyostelium. Eukaryot. Cell 9, 1728–1733

22. Onishi, M., Ko, N., Nishihama, R., and Pringle, J. R. (2013) Distinct roles of Rho1, Cdc42, and Cyt3 in septum formation and abscission during yeast cytokinesis. J. Cell Biol. 202, 311–329

23. Atkins, B. D., Yoshida, S., Saito, K., Wu, C. F., Lew, D. J., and Pellman, D. (2013) Inhibition of Cdc42 during mitotic exit is required for cytokinesis. J. Cell Biol. 202, 231–240

24. De Lozanne, A., and Spudich, J. A. (1987) Disruption of the Dictyostelium myosin heavy chain gene by homologous recombination. Science 236, 1086–1091

25. Fukui, Y. (1990) Structure and function of the cytoskeleton of a Dictyostelium myosin-defective mutant. J. Cell Biol. 110, 367–378

26. Ikeda, F., and Dikic, I. (2008) Atypical ubiquitin chains: new molecular signals. "Protein Modifications: Beyond the Usual Suspects" review series. EMBO Rep. 9, 536–542

27. Kim, H. T., Kim, K. P., Uchiki, T., Gygi, S. P., and Goldberg, A. L. (2009) S5a promotes protein degradation by blocking synthesis of nondegradable forked ubiquitin chains. EMBO J. 28, 1867–1877

28. Nathan, J. A., Kim, H. T., Ling, L., Gygi, S. P., and Goldberg, A. L. (2013) Why do cellular proteins linked to K63-polyubiquitin chains not associate with proteasomes? EMBO J. 32, 552–565

29. Mohants, S., Lee, S., Yadava, N., Dealy, M. J., Johnson, R. S., and Firtel, R. A. (2001) Regulated protein degradation controls PKA function and directed cell migration. Mol. Biol. Cell 12, 185–191

30. Yang, G., Mercado-Uribe, I., Multani, A. S., Sen, S., Shih, I. E. M., Wong, L. Y., Chen, S. Y., Lee, P. H., Chen, C. J., and Santella, R. M. (2002) High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin BI-DNA adduct levels in human hepatocellular carcinoma. Mol. Carcinog. 35, 85–92

31. Khokhlatchev, A., Rabizadeh, S., Xavier, R., and Nedwidek, M. (2002) Identification of a novel Ras-regulated proapoptotic pathway. Curr. Biol. 12, 253–265

32. Palanisamy, N., Varambally, S., and Chinnaiyan, A. M. (2011) Characterization of KRAS rearrangements in metastatic prostate cancer. Cancer Disc. I, 35–43

33. Baker, R., Lewis, S. M., Sasaki, A. T., Wilkerson, E. M., Locasale, J. W., Cantley, L. C., Kuhlman, B., Dohlman, H. G., and Campbell, S. L. (2013) Site-specific monoubiquitination activates Ras by impeding GTase-activating protein function. Nat. Struct. Mol. Biol. 20, 46–52

34. van Engeland, M., Roemen, G. M., Brink, M., Pachen, M. M., Weijenberg, M. P., de Bruïne, A. P., Arends, J. W., van den Brandt, P. A., de Goeij, A. F., and Herman, J. G. (2002) K-ras mutations and RASSF1A promoter methylation in colorectal cancer. Oncogene 21, 3792–3795

35. Zhang, Y. J., Ahsan, H., Chen, Y., Lunn, R. M., Wang, L. Y., Chen, S. Y., Lee, P. H., Chen, C. J., and Santella, R. M. (2002) High frequency of promoter hypermethylation of RASSF1A and its relationship to atilatoxin B1-DNA adduct levels in human hepatocellular carcinoma. Mol. Carcinog. 35, 85–92

36. Khokhlatchev, A., Rabizadeh, S., Xavier, R., and Nedwidek, M. (2002) Identification of a novel Ras-regulated proapoptotic pathway. Curr. Biol. 12, 253–265

37. Pfeifer, G. P., Dammann, R., and Tommasi, S. (2010) RASSF proteins. Curr. Biol. 20, R344–5

38. Sasaki, A. T., and Firtel, R. A. (2009) Spatiotemporal regulation of Ras-GTPases during chemotaxis. Methods Mol. Biol. 571, 333–348

39. Takeda, K., Sasaki, A. T., Ha, H., Seung, H. A., and Firtel, R. A. (2007) Role of Ras-GTPase-activating protein in chemotaxis. J. Biol. Chem. 282, 11874–11884

40. Lee, S., Cramer, F. I., Sasaki, A. M., McLeod, I. X., Dong, Y., Okumura, K., Yates, J. R., 3rd, Parent, C. A., and Firtel, R. A. (2005) cAMP complex 2 integrates cell movement during chemotaxis and signal relay in Dictyostelium. Mol. Biol. Cell 16, 4572–4583